| WIN Project Activity
|
|
Chairperson: Thomas Tursz
|
Today there are more than 14,000,000 new cancers each year world wide, and less than 50% are cured. The main cause is
late detection and inappropriate treatment based on statistical population approaches. The shift from past to future
medicine based on prevention, early diagnosis and efficient individualized treatments could be dramatically accelerated
from 50 years to a 3-5 year timeline, through a coordinated efficient worldwide initiative bringing together the élite
of academic industry and a coordinated governmental strategy. To this aim, the WIN Consortium (worldwide innovative
networking in cancer personalized medicine) is a joint initiative of the Institut Gustave Roussy and the University
of Texas M. D. Anderson Cancer Center (MDACC), in association with 26 élite leading cancer care institutions in Europe,
United States of America, Canada, Middle East and Asia. All European institutes are OECI members. The major goal of the
WIN Consortium is to accelerate translation of ground-breaking discoveries made in personalized cancer medicine from
the bench to the bedside and to promote new types of interactions between academy and industry worldwide.
This is a worldwide initiative, across the continents, and the WIN Consortium aims to build new strategic alliances
in oncology, to improve early diagnosis of cancer, and to establish new treatment strategies based on rational
individualized selection of treatments.
The management of the WIN Consortium is assured by Dr. Vladimir Lazar from IGR (France), in his capacity of co-ordinator
of the WIN Consortium and Chairman of the Steering Committee, and by Pr. John Mendelsohn from MDACC (USA), in his capacity
of President of the WIN Consortium. The management proposes a strategic plan based on the most advanced scientific and
technologic achievements and brings together worldwide key opinion leaders in oncology.
The WIN Consortium is extremely focused on five objectives:
1. early diagnosis as the most efficient way to improve clinical outcome;
2. individualized treatment and therapeutic combinations based on innovative technologies available within the consortium;
3. strategic positioning with pharmaceutical companies with innovative drug associations and efficient clinical trials conducted simultaneously across the continents;
4. standardisation, harmonization and worldwide coordination of academics;
5. education and scientific dissemination through its annual WIN symposium
The WIN consortium is an operational organization that has decided to join forces and knowledge in order to considerably
improve health care in oncology and to lead to important societal benefits in terms of cost of cancer health care.
|
|
|